Major haemorrhage is a leading cause of early death. It is often unexpected, and may require large quantities of different blood products urgently – a daily challenge for blood services and health systems. We’re using our Massive Transfusion Registry together with a network of specialists working across prehospital and hospital settings to develop new evidence to inform recommendations and guide clinical decision-making on management of critical bleeding.
Critically ill patients in intensive care often receive blood transfusions, yet major evidence gaps still exist regarding the optimal use of blood components and other therapies in this context. We are conducting observational and interventional studies to evaluate the efficacy and safety of transfusions in critically ill patients, providing data that will inform policy and guide clinical decision-making in transfusion support for patients in the critical care setting.
Patients with blood cancers and other blood diseases are the major users of red cell and platelet products. However, much of the evidence base for transfusion practice in this area is weak and in some cases, outdated, as treatments of these disorders have advanced significantly in recent years. We are investigating optimal transfusion and alternative treatment strategies and products, to improve clinical management and outcomes, and reduce transfusion risks.
Immunoglobulin (Ig) therapy, made from plasma, is used to treat patients with a wide range of conditions; for patients with blood cancers, it is generally used to prevent or treat infections. Ig use accounts for over half Australia’s national blood budget, and its use continues to grow. Our research investigates the efficient and effective use of Ig, including optimal duration of use, clinical outcomes for patients receiving Ig, and other interventions to manage infectious risks.
Our health economic analyses are conducted alongside each research stream, embedded within each of the research projects. This approach provides important new information to improve health system performance and deliver quality, cost-effective care for patients.
Research Project Areas
Major haemorrhage management
- Integration of prehospital haemorrhage and transfusion datasets
- Developing a national transfusion dataset, through expansion of the Australian & New Zealand Massive Transfusion Registry (ANZ MTR)
Access and use of blood products for major haemorrhage
- Modelling demand and availability of blood products
- Uptake and impact of point-of-care testing on coagulation management and blood use
New approaches to massive transfusion support
- Fibrinogen concentrate for the treatment of critical bleeding
- Development of clinical decision support systems for critical bleeding
Transfusion support in critically ill patients
- Observational studies of blood product use in intensive care
- Platelet transfusion thresholds in sepsis
Management of anaemia and bleeding in haematologic malignancies
- Alternatives to conventional platelet transfusion to prevent and manage bleeding
- Optimising red blood cell transfusion strategies in myelodysplasia
- Observational studies of immunoglobulin use in patients with blood cancers
- Comparing immunoglobulin therapy versus antibiotics for the prevention and treatment of infection
- Convalescent plasma for treatment of SARS-CoV-2 infection (COVID-19)
We have a number of projects available for students looking to undertake research as part of an Honours, Masters or PhD program. A sample of projects are listed below. Please contact us if you are interested in joining our team.
- Prehospital blood product availability and use across Australia: see project details here
- Emergency hospital admission for critical bleeding and massive transfusion: see project details here
- Critical bleeding and surgery: see project details here
- Find more